Lysis of human chondrosarcoma cells by cytolytic T lymphocytes recognizing a MAGE-A3 antigen presented by HLA-A1 molecules

Journal of Orthopaedic Research

Volumn 25, Issue 5, 2007, Pages 678-684

  Bluman, Eric M ^a   Coulie, Pierre G ^b   Xiaojuan, Sun ^a   Machan, Jason ^a   Lin, Chouzao ^a   Meitner, Patricia A ^a   Block, Joel A ^c   Terek, Richard M ^a,d  

^a BROWN UNIVERSITY   (United States)

^b UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^c RUSH UNIVERSITY MEDICAL CENTER   (United States)

^d NONE   (United States)

Author keywords

HLA A1 molecules; Human chondrosarcoma cells; MAGE A3 antigen; T lymphocytes

Indexed keywords

GAMMA INTERFERON; HLA A1 ANTIGEN; MELANOMA ANTIGEN; MELANOMA ANTIGEN A3; UNCLASSIFIED DRUG;

ARTICLE; CANCER IMMUNOTHERAPY; CELL CLONING; CELL SPECIFICITY; CHONDROSARCOMA; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOLYSIS; CYTOTOXIC T LYMPHOCYTE; GENE TARGETING; GENETIC SUSCEPTIBILITY; HUMAN; HUMAN CELL; IN VITRO STUDY; INCUBATION TIME; PRIORITY JOURNAL; PROTEIN EXPRESSION; SARCOMA CELL; SENSITIVITY ANALYSIS;

ANTIGEN PRESENTATION; ANTIGENS, NEOPLASM; BONE NEOPLASMS; CELL LINE, TUMOR; CHONDROSARCOMA; EPITOPES; FLOW CYTOMETRY; HLA-A1 ANTIGEN; HUMANS; IMMUNOTHERAPY; INTERFERON TYPE II; NEOPLASM PROTEINS; T-LYMPHOCYTES, CYTOTOXIC;

EID: 34248360785     PISSN: 07360266     EISSN: None     Source Type: Journal    
DOI: 10.1002/jor.20368     Document Type: Article

References (37)

1. Springfield DS, Gebhardt MC, McGuire MH. 1996. Chondrosarcoma: a review. Instr Course Lect 45:417-424.
2. Sheth DS, Yasko AW, Johnson ME, et al. 1996. Chondrosarcoma of the pelvis. Prognostic factors for 67 patients treated with definitive surgery. Cancer 78:745-750.
3. Atkins MB. 2002. Interleukin-2: clinical applications. Semin Oncol 29:12-17.
4. Plautz GE, Cohen PA, Shu S. 2003. Considerations on clinical use of T cell immunotherapy for cancer. Arch Immunol Ther Exp (Warsz) 51:245-257.
5. Garrido F, Cabrera T, Concha A, et al. 1993. Natural history of HLA expression during tumour development. Immunol Today 14:491-499.
6. Garrido F, Ruiz-Cabello F. 1991. MHC expression on human tumors-its relevance for local tumor growth and metastasis. Semin Cancer Biol 2:3-10.
7. Garrido F, Ruiz-Cabello F, Cabrera T, et al. 1997. Implications for immunosurveillance of altered HLA class I phenotypes in human tumours. Immunol Today 18:89-95.
8. Lin C, Mak S, Meitner PA, et al. 2002. Cancer/testis antigen CSAGE is concurrently expressed with MAGE in chondrosarcoma. Gene 285:269-278.
9. Brasseur F, Marchand M, Vanwijck R, et al. 1992. Human gene MAGE-1, which codes for a tumor-rejection antigen, is expressed by some breast tumors. Int J Cancer 52:839-841.
10. Mori M, Inoue H, Mimori K, et al. 1996. Expression of MAGE genes in human colorectal carcinoma. Ann Surg 224:183-188.
11. Tahara K, Sadanaga N, Nagashima H, et al. 2000. MAGE-specific cytotoxic T lymphocytes require non-specific CD54 adherence receptors on carcinoma cells. Int J Oncol 17: 805-810.
12. Weynants P, Lethe B, Brasseur F, et al. 1994. Expression of mage genes by non-small-cell lung carcinomas. Int J Cancer 56:826-829.
13. Chomez P, De Backer O, Bertrand M, et al. 2001. An overview of the MAGE gene family with the identification of all human members of the family. Cancer Res 61:5544-5551.
14. Block JA, Inerot SE, Gitelis S, et al. 1991. Synthesis of chondrocytic keratan sulphate-containing proteoglycans by human chondrosarcoma cells in long-term cell culture. J Bone Joint Surg Am 73:647-658.
15. Coulie PG, Karanikas V, Colau D, et al. 2001. A monoclonal cytolytic T-lymphocyte response observed in a melanoma patient vaccinated with a tumor-specific antigenic peptide encoded by gene MAGE-3. Proc Natl Acad Sci USA 98: 10290-10295.
16. Wizigmann-Voos S, Breier G, Risau W, et al. 1995. Up-regulation of vascular endothelial growth factor and its receptors in von Hippel-Lindau disease-associated and sporadic hemangioblastomas. Cancer Res 55:1358-1364.
17. Livak KJ, Schmittgen TD. 2001. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25:402-408.
18. Hiraki A, Ikeda K, Yoshino T, et al. 2001. Tumor-specific cytotoxic T lymphocyte responses against chondrosarcoma with HLA haplotype loss restricted by the remaining HLA class I allele. Biochem Biophys Res Commun 286:786-791.
19. Joyner DE, Damron TA, Aboulafia A, et al. 2006. Heterogeneous expression of melanoma antigen (hMAGE) mRNA in mesenchymal neoplasia. Tissue Antigens 68:19-27.
20. Boehm U, Klamp T, Groot M, et al. 1997. Cellular responses to interferon-gamma. Annu Rev Immunol 15: 749-795.
21. Hofbauer GF, Geertsen R, Laine E, et al. 2001. Impact of interferons on the expression of melanoma-associated antigens in melanoma short-term cell cultures. Melanoma Res 11:213-218.
22. Le Poole IC, Riker AI, Quevedo ME, et al. 2002. Interferon-gamma reduces melanosomal antigen expression and recognition of melanoma cells by cytotoxic T cells. Am J Pathol 160:521-528.
23. Vlock DR, Toporowicz A, Arnold B. 1992. Modulation by interferon alpha and gamma of the expression of a melanoma-associated antigen detected by autologous antibody. Melanoma Res 2:105-114.
24. Abele R, Tampe R. 2006. Modulation of the antigen transport machinery TAP by friends and enemies. FEBS Lett 580:1156-1163.
25. Satoh E, Mabuchi T, Satoh H, et al. 2006. Reduced expression of the transporter associated with antigen processing 1 molecule in malignant glioma cells, and its restoration by interferon-gamma and -beta. J Neurosurg 104:264-271.
26. Strehl B, Seifert U, Kruger E, et al. 2005. Interferon-gamma, the functional plasticity of the ubiquitin-proteasome system, and MHC class I antigen processing. Immunol Rev 207:19-30.
27. Hsu L, Finke JH, Scott JW, et al. 1981. CTL helper factor(s) produced by peritoneal cells of mice immunized to Listeria monocytogenes: relationship to interferon. J Interferon Res 1:271-285.
28. Suzuki R, Suzuki S, Ebina N, et al. 1985. Suppression of alloimmune cytotoxic T lymphocyte (CTL) generation by depletion of NK cells and restoration by interferon and/or interleukin 2. J Immunol 134:2139-2148.
29. Mori M, Beatty PG, Graves M, et al. 1997. HLA gene and haplotype frequencies in the North American population: the National Marrow Donor Program Donor Registry. Transplantation 64:1017-1027.
30. van der BP,Bastin J, Gajewski T, et al. 1994. A peptide encoded by human gene MAGE-3 and presented by HLA-A2 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE-3. Eur J Immunol 24:3038-3043.
31. Marchand M, Punt CJ, Aamdal S, et al. 2003. Immunisation of metastatic cancer patients with MAGE-3 protein combined with adjuvant SBAS-2: a clinical report. Eur J Cancer 39:70-77.
32. Marchand M, van Baren N, Weynants P, et al. 1999. Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1. Int J Cancer 80: 219-230.
33. Schuler-Thurner B, Dieckmann D, Keikavoussi P, et al. 2000. Mage-3 and influenza-matrix peptide-specific cytotoxic T cells are inducible in terminal stage HLA- A2.1+ melanoma patients by mature monocyte-derived dendritic cells. J Immunol 165:3492-3496.
34. Attia P, Phan GQ, Maker AV, et al. 2005. Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J Clin Oncol 23:6043-6053.
35. Lin C, McGough R, Aswad B, et al. 2004. Hypoxia induces HIF-1alpha and VEGF expression in chondrosarcoma cells and chondrocytes. J Orthop Res 22:1175-1181.
36. McGough RL, Aswad BI, Terek RM. 2002. Pathologic neovascularization in cartilage tumors. Clin Orthop Relat Res 76-82.
37. McGough RL, Lin C, Meitner P, et al. 2002. Angiogenic cytokines in cartilage tumors. Clin Orthop Relat Res 62-69.